Edison has released a report on LTR Pharma, highlighting the clinical validation of SPONTAN as a fast-acting intranasal treatment for erectile dysfunction and its progression toward regulatory submission.
The report also covers our platform expansion into new markets through ROXUS and OROFLOW, alongside portfolio diversification via our recent investment in LevOmega.
The author notes:
“With early access having commenced in Australia and its FDA regulatory pathway progressing, LTR is expanding the application of its intranasal platform. Strategic diversifications into ROXUS (US personalised medicine) and OROFLOW (oesophageal motility disorders) position LTR to capture further value across multiple billion-dollar markets.”